Blueprint Medicines/BPMC

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Blueprint Medicines

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Ticker

BPMC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

645

BPMC Metrics

BasicAdvanced
$6.9B
Market cap
-
P/E ratio
-$4.73
EPS
0.65
Beta
-
Dividend rate
$6.9B
0.65
3.759
3.427
164.405
192.455
-11.13%
-24.40%
-79.53%
23.82
22.1
22.1
-15.64
37.94%
-51.26%
-29.61%
-5.77%

What the Analysts think about BPMC

Analyst Ratings

Majority rating from 18 analysts.
Buy

BPMC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
92.71% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$96M
33.66%
Net income
$89M
-180.34%
Profit margin
92.71%
-160.11%

BPMC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20.59%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.19
-$2.20
-$1.82
-$1.32
-
Expected
-$2.54
-$2.37
-$2.04
-$1.66
-$1.29
Surprise
-13.77%
-7.06%
-10.78%
-20.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Blueprint Medicines stock?

Blueprint Medicines (BPMC) has a market cap of $6.9B as of July 04, 2024.

What is the P/E ratio for Blueprint Medicines stock?

The price to earnings (P/E) ratio for Blueprint Medicines (BPMC) stock is 0 as of July 04, 2024.

Does Blueprint Medicines stock pay dividends?

No, Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Blueprint Medicines dividend payment date?

Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders.

What is the beta indicator for Blueprint Medicines?

Blueprint Medicines (BPMC) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Blueprint Medicines stock

Buy or sell Blueprint Medicines stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing